Developing new antiviral agents using genetically engineered peptides
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
['FUNDING_OTHER'] · INDIANA UNIVERSITY INDIANAPOLIS · NIH-10996138
This study is exploring new types of molecules that could help create better antiviral treatments for viruses like the coronavirus, aiming to find more effective options for patients who need them.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | INDIANA UNIVERSITY INDIANAPOLIS (nih funded) |
| Locations | 1 site (INDIANAPOLIS, UNITED STATES) |
| Trial ID | NIH-10996138 on ClinicalTrials.gov |
What this research studies
This research focuses on creating bicyclic peptides, which are specialized molecules that can bind more effectively to viral proteins, potentially leading to new antiviral treatments. By utilizing a technique called phage display, researchers aim to discover high-affinity peptide ligands from large libraries of these peptides. The study seeks to overcome current limitations in peptide development by using genetic code expansion to produce these bicyclic peptides, which could enhance their effectiveness against viruses like the novel coronavirus. Patients may benefit from new antiviral therapies that are more effective and targeted.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals affected by viral infections, particularly those caused by coronaviruses.
Not a fit: Patients with non-viral infections or those not affected by the targeted viruses may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of novel antiviral medications that are more effective against viral infections.
How similar studies have performed: Other research has shown promise in using similar peptide-based approaches for antiviral drug development, indicating potential for success in this area.
Where this research is happening
INDIANAPOLIS, UNITED STATES
- INDIANA UNIVERSITY INDIANAPOLIS — INDIANAPOLIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: THARP, JEFFERY MICHEAL — INDIANA UNIVERSITY INDIANAPOLIS
- Study coordinator: THARP, JEFFERY MICHEAL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.